2018
Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecologic Oncology 2018, 150: 253-260. PMID: 29884437, DOI: 10.1016/j.ygyno.2018.05.025.Peer-Reviewed Original ResearchConceptsCisplatin-based chemotherapyClinical trial organizationsGerm cell tumorsFive-year event-free survivalMalignant ovarian germ cell tumorsOvarian germ cell tumorsAge groupsCarboplatin-based chemotherapyTreatment-related toxicityEvent-free survivalEligible patientsExcellent OSMetastatic diseaseOverall survivalClinical outcomesFrontline treatmentSurvival outcomesMean agePeak incidenceCell tumorsDysgerminomaChemotherapyPatientsTrials OrganizationCarboplatinComparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium
Frazier AL, Stoneham S, Rodriguez-Galindo C, Dang H, Xia C, Olson TA, Murray MJ, Amatruda JF, Shaikh F, Pashankar F, Billmire D, Krailo M, Stark D, Brougham MFH, Nicholson JC, Hale JP. Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium. European Journal Of Cancer 2018, 98: 30-37. PMID: 29859339, DOI: 10.1016/j.ejca.2018.03.004.Peer-Reviewed Original ResearchConceptsChildren's Oncology GroupEvent-free survivalOncology GroupClinical trialsGerm cell tumor patientsCarboplatin-based regimensCisplatin-based regimensParametric cure modelsLeukemia groupTumor patientsStandard riskChildren's CancerRegimensCancerRiskTrialsGroupCure modelPatientsCarboplatinInternational ConsortiumCisplatin
2014
Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States
Frazier AL, Hale JP, Rodriguez-Galindo C, Dang H, Olson T, Murray MJ, Amatruda JF, Thornton C, Arul GS, Billmire D, Shaikh F, Pashankar F, Stoneham S, Krailo M, Nicholson JC. Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States. Journal Of Clinical Oncology 2014, 33: 195-201. PMID: 25452439, PMCID: PMC4279239, DOI: 10.1200/jco.2014.58.3369.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAlpha-FetoproteinsBiomarkers, TumorChildChild, PreschoolClinical Trials as TopicDisease-Free SurvivalEndodermal Sinus TumorEvidence-Based MedicineFemaleHumansMaleModels, StatisticalNeoplasm StagingNeoplasms, Germ Cell and EmbryonalPredictive Value of TestsPrognosisRetrospective StudiesRisk AssessmentRisk FactorsUnited KingdomUnited StatesConceptsGerm cell tumorsYolk sac tumorPediatric germ cell tumorsClinical trial dataAlpha-fetoproteinTumor siteOncology GroupCell tumorsMalignant pediatric germ cell tumorsPediatric extracranial germ cell tumorLong-term disease-free survivalEvidence-based risk stratificationExtracranial germ cell tumorsTrial dataPure yolk sac tumorPoor-risk groupStage IV diseaseDisease-free survivalPercentage of patientsChildren's Oncology GroupElevated alpha-fetoproteinPlatinum-based therapyClinical trial organizationsParametric cure modelsLeukemia group
2012
Children's Oncology Group's 2013 blueprint for research: Rare tumors
Rodriguez‐Galindo C, Krailo M, Frazier L, Chintagumpala M, Amatruda J, Katzenstein H, Malogolowkin M, Spector L, Pashankar F, Meyers R, Tomlinson G, Committee O. Children's Oncology Group's 2013 blueprint for research: Rare tumors. Pediatric Blood & Cancer 2012, 60: 1016-1021. PMID: 23255219, PMCID: PMC4304764, DOI: 10.1002/pbc.24428.Peer-Reviewed Original ResearchConceptsGerm cell tumorsCell tumorsRare cancersChildren's Oncology Group's 2013 blueprintInternational phase 3 clinical trialsPhase 3 clinical trialsEvidence-based definitionIntraocular retinoblastomaAdvanced carcinomaRisk stratificationInfrequent malignancyRare tumorClinical trialsClinical studiesLiver tumorsTumorsBiologic studiesChildrenCancerRetinoblastomaCarcinomaMalignancyHepatoblastomaYearsTrials
2005
MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use.
Pashankar FD, O'Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. Journal Of Nuclear Medicine 2005, 46 Suppl 1: 55s-61s. PMID: 15653652.Peer-Reviewed Original ResearchMeSH Keywords3-IodobenzylguanidineAnimalsChildChild, PreschoolClinical Trials as TopicHumansInfantInfant, NewbornNeuroblastomaOctreotidePatient SelectionPentetic AcidPractice Guidelines as TopicPractice Patterns, Physicians'Radiation InjuriesRadionuclide ImagingRadiopharmaceuticalsSomatostatinTreatment OutcomeConceptsSolid tumorsCertain pediatric tumorsSomatostatin receptor analoguesPediatric solid tumorsMetaiodobenzylguanidine scanNuclear imaging techniquesBone scanPediatric tumorsFalse transmitterTherapeutic useCell membrane receptorsReceptor analoguesYoung adultsTumorsMolecular targetsCurrent conceptsMIBGScansMembrane receptorsSpecific ligandsImaging techniquesChildrenSubcellular organellesCellular proteinsDiagnosis